MacroGenics (NASDAQ: MGNX) — Company Overview, News & Financial Data
MacroGenics develops monoclonal antibody therapeutics for cancer and autoimmune diseases, advancing precision medicine and clinical programs.
MacroGenics
MacroGenics (NASDAQ:MGNX) is a biotechnology company focused on creating and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. MacroGenics leverages a variety of technology platforms to engineer antibodies with the potential to address unmet medical needs. Its portfolio includes product candidates in different stages of clinical development, targeting a range of malignancies and autoimmune disorders. The company's objectives revolve around advancing its clinical programs, continuing robust research and development efforts, and collaboration with leading pharmaceutical companies to bring transformative treatment options to patients. MacroGenics is dedicated to improving patient outcomes and making a significant impact in the field of precision medicine.
Snapshot
Operations
Products and/or services of MacroGenics
- Margetuximab, an innovative monoclonal antibody targeting HER2 for the treatment of metastatic breast cancer.
- Enoblituzumab, a monoclonal antibody against B7-H3 for solid tumors, including head and neck cancer.
- Lorigerlimab, an anti-PD-1 monoclonal antibody for advanced solid tumors.
- Teplizumab, under development for the delay or prevention of type 1 diabetes in at-risk individuals.
- MGD013, a bispecific DART molecule targeting PD-1 and LAG-3 for various cancer types.
MacroGenics executive team
- Eric Blasius RisserCEO, President & Director
- James KarrelsSenior VP & CFO
- Ezio BonviniSenior VP of Research & Chief Scientific Officer
- Araba Lamouse-SmithVice President of Technical Operations
- Jeffrey Stuart PetersSenior VP, Corporate Secretary, General Counsel & Corporate Compliance Officer
- Steve HarigSenior Vice President of Human Resources
- Harish KrishnaswamySenior Vice President of Business Development & Portfolio Planning
- Frank George PeraboVice President & Interim Head of Clinical Development
- Beth SmithVP, Controller & Treasurer
Key financials
Reported results for MacroGenics, in USD.
- Market cap
- 154.2M
- Revenue (TTM)
- 175.1M
- P/E ratio
- —
- EPS (diluted, TTM)
- -1.8
- Dividend yield
- —
- Profit margin
- -8.3%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 149.5M | -72.8M | -74.6M | |
| 148.3M | -110.6M | -67M | |
| 57.2M | -168.2M | -9.1M | |
| 151.9M | -121.4M | -120M |